Robin Joyce

7.7k total citations · 2 hit papers
94 papers, 4.0k citations indexed

About

Robin Joyce is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Robin Joyce has authored 94 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pathology and Forensic Medicine, 36 papers in Oncology and 34 papers in Immunology. Recurrent topics in Robin Joyce's work include Lymphoma Diagnosis and Treatment (34 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Immunotherapy and Immune Responses (18 papers). Robin Joyce is often cited by papers focused on Lymphoma Diagnosis and Treatment (34 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Immunotherapy and Immune Responses (18 papers). Robin Joyce collaborates with scholars based in United States, Israel and United Kingdom. Robin Joyce's co-authors include David Avigan, Myron S. Czuczman, Nancy L. Bartlett, Thomas E. Witzig, Leo I. Gordon, Brad Pohlman, Christos Emmanouilides, Fernando Cabanillas, Antonio J Grillo-López and Christine A. White and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Robin Joyce

91 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

2002 841 citations Thomas E. Witzig, Leo I. Gordon et al. profile →
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

2011 809 citations John Koreth, Ken‐ichi Matsuoka et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Joyce United States	26	1.5k	1.5k	1.4k	848	811	94	4.0k
Isabelle Bence‐Bruckler Canada	18	1.5k 0.9×	853 0.6×	2.0k 1.4×	995 1.2×	459 0.6×	62	3.5k
Roch Houot France	38	2.7k 1.7×	1.9k 1.2×	1.5k 1.0×	462 0.5×	250 0.3×	181	4.3k
Leslie Popplewell United States	34	2.8k 1.8×	1.1k 0.7×	2.0k 1.4×	302 0.4×	756 0.9×	202	5.0k
Diying Shen China	10	1.2k 0.8×	905 0.6×	1.7k 1.2×	1.1k 1.2×	310 0.4×	34	3.0k
Arne Kolstad Norway	28	1.9k 1.2×	720 0.5×	2.1k 1.5×	718 0.8×	239 0.3×	121	3.5k
Roland Repp Germany	36	1.4k 0.9×	2.2k 1.4×	1.1k 0.8×	1.7k 2.0×	406 0.5×	85	4.3k
Andreas Viardot Germany	28	3.0k 1.9×	1.1k 0.7×	2.0k 1.4×	920 1.1×	842 1.0×	131	4.6k
Hartmut Kirchner Germany	32	1.9k 1.3×	1.2k 0.8×	1.7k 1.2×	406 0.5×	1.0k 1.3×	117	5.0k
B.K. Dallaire United States	16	2.0k 1.3×	1.4k 0.9×	2.7k 1.9×	1.5k 1.8×	419 0.5×	19	5.0k
Andrei R. Shustov United States	34	2.5k 1.6×	2.0k 1.3×	3.3k 2.4×	311 0.4×	567 0.7×	158	5.3k

Countries citing papers authored by Robin Joyce

Since Specialization

Citations

This map shows the geographic impact of Robin Joyce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Joyce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Joyce more than expected).

Fields of papers citing papers by Robin Joyce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Joyce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Joyce. The network helps show where Robin Joyce may publish in the future.

Co-authorship network of co-authors of Robin Joyce

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Joyce. A scholar is included among the top collaborators of Robin Joyce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Joyce. Robin Joyce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Merryman, Reid W., Justin Rhoades, Kan Xiong, et al.. (2024). Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma. HemaSphere. 8(4). e47–e47. 1 indexed citations

Dias, Ajoy, Laura E. Dodge, Jon Arnason, et al.. (2024). High CD34‐positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft‐versus‐host disease or mortality. Transfusion. 64(6). 1068–1075.

Zwicker, Jeffrey I., Mäneka Puligandla, Benjamin L. Schlechter, et al.. (2020). Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Advances. 4(10). 2254–2260. 16 indexed citations

Lampson, Benjamin L., Haesook T. Kim, Matthew S. Davids, et al.. (2017). Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia. Blood. 130. 1734–1734. 4 indexed citations

Jain, Salvia, Dina Stroopinsky, Yin Li, et al.. (2015). Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 126(3). 354–362. 28 indexed citations

Wong, Michael T., et al.. (2015). Continuous positive airway pressure-associated cutaneous amoebiasis in an immunosuppressed patient. British Journal of Dermatology. 174(3). 625–628. 3 indexed citations

Nahas, Myrna, Dina Stroopinsky, Hasan Rajabi, et al.. (2015). MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia. Blood. 126(23). 2473–2473. 2 indexed citations

Stroopinsky, Dina, Jacalyn Rosenblatt, Keisuke Ito, et al.. (2013). MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. Cancer Research. 73(17). 5569–5579. 41 indexed citations

Matasar, Matthew J., Myron S. Czuczman, Maria Alma Rodriguez, et al.. (2013). Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 122(4). 499–506. 45 indexed citations

10.

Shaughnessy, Paul, Joseph P. Uberti, Steven M. Devine, et al.. (2012). Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplantation. 48(6). 777–781. 29 indexed citations

11.

Rosenblatt, Jacalyn, Brett Glotzbecker, Heidi Mills, et al.. (2011). PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine. Journal of Immunotherapy. 34(5). 409–418. 237 indexed citations

12.

Koreth, John, Ken‐ichi Matsuoka, Haesook T. Kim, et al.. (2011). Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. New England Journal of Medicine. 365(22). 2055–2066. 809 indexed citations breakdown →

13.

Avigan, David, Jacalyn Rosenblatt, Baldev Vasir, et al.. (2007). Vaccination with DC/Multiple Myeloma Fusions in Conjunction with Stem Cell Transplantation.. Blood. 110(11). 578–578. 1 indexed citations

14.

Williams, Gethin, Matthew R. Palmer, J. Anthony Parker, & Robin Joyce. (2006). Case Report : Extravazation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin ^® ): A Case Report. Cancer Biotherapy and Radiopharmaceuticals. 21(2). 101–105. 28 indexed citations

15.

Ely, Pamela, et al.. (2006). 90Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.. Blood. 108(11). 2752–2752.

16.

Treon, Steven P., Zachary R. Hunter, Jeffrey Matous, et al.. (2005). Phase II Study of Bortezomib in Waldenstrom’s Macroglobulinemia: Results of WMCTG Trial 03-248.. Blood. 106(11). 490–490. 12 indexed citations

17.

Gordon, Leo I., Thomas E. Witzig, Arturo Molina, et al.. (2004). Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma. Clinical Lymphoma. 5(2). 98–101. 82 indexed citations

18.

Exley, Mark A., Syed Muhammad Tahir, Olivia Cheng, et al.. (2001). Cutting Edge: A Major Fraction of Human Bone Marrow Lymphocytes Are Th2-Like CD1d-Reactive T Cells That Can Suppress Mixed Lymphocyte Responses. The Journal of Immunology. 167(10). 5531–5534. 127 indexed citations

19.

Krasner, Carolyn & Robin Joyce. (2001). Zevalin™: 90Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin's Lymphoma. Current Pharmaceutical Biotechnology. 2(4). 341–349. 37 indexed citations

20.

Richardson, Paul G., David Avigan, Joseph G. Ibrahim, et al.. (2001). A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Bone Marrow Transplantation. 28(5). 447–454. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact